Novel 13-transmembrane protein expressed in prostate cancer
AssigneeAgensys, Inc.
InventorsDaniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran
Life of this patent
Estimating the term…
Abstract
A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24P4C12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and/or therapeutic target for prostate and other cancers.
Claims41
A polynucleotide that encodes a 24P4C12 polypeptide, wherein the polynucleotide is selected from the group consisting of:
- (a) a polynucleotide having the sequence as shown in FIGS. 1A-1D (SEQ ID NO:
- 1) or FIG. 1E (SEQ ID NO:
- 3), wherein T can also be U;
- (b) a polynucleotide having the sequence as shown in FIGS. 1A-1D (SEQ ID NO:
- 1), from nucleotide residue number 6 through nucleotide residue number 2138, wherein T can also be U;
- (c) a polynucleotide encoding a 24P4C12 polypeptide whose sequence is encoded by a cDNA contained in the plasmids designated p24P4C12-GTE5 or p24P4C12-GTE9 deposited with American Type Culture Collection as Designation Nos. 207129 and 207084, respectively;
- (d) a polynucleotide encoding a 24P4C12 protein having the amino acid sequence shown in FIGS. 1A-1D (SEQ ID NO:
- 2) or FIG. 1E (SEQ ID NO:
- 4);
- and
- (e) a polynucleotide that is fully complementary to a polynucleotide of any one of (a)-(d).
A polynucleotide that encodes a polypeptide that is at least 90% identical to the amino acid sequence shown in FIGS. 1A-1D (SEQ ID NO:
- 2) or FIG. 1E (SEQ ID NO:
- 4) over its entire length.
A polynucleotide that encodes a 24P4C12 polypeptide, wherein the polypeptide includes an amino acid sequence selected from the group consisting of NRSC (SEQ ID NO:
- 8), NSTG (SEQ ID NO:
- 9), NMTV (SEQ ID NO:
- 10), NDTT (SEQ ID NO:
- 11), NLSA (SEQ ID NO:
- 12), NISS (SEQ ID NO:
- 13), NTSC (SEQ ID NO:
- 14), NSSC (SEQ ID NO:
- 15), NGSL (SEQ ID NO:
- 16), SFR, SVK, SSK, TLR, SAK, SGR, SCTD (SEQ ID NO:
- 17), SVAE (SEQ ID NO:
- 18), SCPE (SEQ ID NO:
- 19), TVGE (SEQ ID NO:
- 20), SVQE (SEQ ID NO:
- 21), RDEDDEAY (SEQ ID NO:
- 22), GAYCGM (SEQ ID NO:
- 23), GMGENK (SEQ ID NO:
- 24), GVPWNM (SEQ ID NO:
- 25), GLIDSL (SEQ ID NO:
- 26), GIYYCW (SEQ ID NO:
- 27), GASISQ (SEQ ID NO:
- 28), GQMMST (SEQ ID NO:
- 29), GLFWTL (SEQ ID NO:
- 30), GAFASF (SEQ ID NO:
- 31), LGKK (SEQ ID NO:
- 32), and LFILLLRLVAGPLVLVILGVL (SEQ ID NO:
- 33).
A polynucleotide that encodes a 24P4C12 polypeptide, wherein the polypeptide includes a transmembrane domain shown in FIGS. 1A-1D.
An assay for detecting the presence of 24P4C12 mRNA in a biological sample comprising:
- (a) producing cDNA from the sample by reverse transcription using at least one primer;
- (b) amplifying the cDNA so produced using 24P4C12 polynucleotides as sense and antisense primers to amplify 24P4C12 cDNAs therein;
- (c) detecting the presence of the amplified 24P4C12 cDNA,
- wherein the 24P4C12 polynucleotides used as the sense and antisense probes are capable of amplifying the 24P4C12 cDNA contained within a plasmids designated p24P4C12-GTE5 or p24P4C12-GTE9, deposited with American Type Culture Collection as Designation Nos. 207129 and 207084, respectively.
A method of detecting the presence of a cancer expressing 24P4C12 protein that comprises determining the level of 24P4C12 protein expressed by cells in a test tissue sample from an individual and comparing the level so determined to the level of 24P4C12 expressed in a corresponding normal sample, the presence of elevated 24P4C12 protein in the test sample relative to the normal sample providing an indication of the presence of such cancer in the individual.
A method of monitoring 24P4C12 gene products comprising determining the status of 24P4C12 gene products expressed by cells in a test tissue sample from an individual and comparing the status so determined to the status of 24P4C12 gene products in a corresponding normal sample, the presence of aberrant 24P4C12 gene products in the test sample relative to the normal sample providing an indication of disregulated cell growth within the individual.
A method of diagnosing the presence of cancer in an individual comprising:
- (a) determining the level of 24P4C12 mRNA expressed in a test sample obtained from the individual;
- and
- (b) comparing the level so determined to the level of 24P4C12 mRNA expressed in a comparable known normal tissue sample,
- the presence of elevated 24P4C12 mRNA expression in the test sample relative to the normal tissue sample providing an indication of the presence of cancer.
A method of diagnosing the presence of cancer in an individual comprising:
- (a) determining the level of 24P4C12 protein expressed in a test sample obtained from the individual;
- and
- (b) comparing the level so determined to the level of 24P4C12 protein expressed in a comparable known normal tissue sample,
- the presence of elevated 24P4C12 protein in the test sample relative to the normal tissue sample providing an indication of the presence of cancer.
A method for identifying a 24P4C12 specific binding agent comprising:
- (a) contacting a candidate agent that binds 24P4C12 with H38087;
- and
- (b) determining whether the candidate agent binds H38087, a lack of binding of the candidate agent to H38087 being indicative of 24P4C12 specificity.
A vaccine composition for the treatment of a cancer expressing 24P4C12 comprising an immunogenic portion of a 24P4C12 protein and a physiologically acceptable carrier.
Dependencies are inferred from the claim text.